Clinical efficiency and safety of madopar and pramipexole in treatment of Parkinson's disease / 中国生化药物杂志

ABSTRACT

Objective To study and analyze the clinical efficacy and safety of madopar and pramipexole in treatment of Parkinson's disease.Methods 120 cases with Parkinson's disease admitted in the Sixth Hospital of Ningbo City from Mar 2013 to Mar 2014 were randomly and evenly divided into combination group and single group,each group had 60 cases. The single group were treated with madopar,while combination group were treated with madopar and pramipexole. The treatment efficiency,incidence and score of adverse reactions in two groups were recorded and compared in order to assess their efficiency and safety. Results The treatment efficiency,adverse reactions in combination group (95.00%,20.00%)were better than single group (58.33%,83.33%),the differences were statistically significant (P<0.05).The score of adverse reactions in combination group after treatment was better than before treatment,the difference was significant(P<0.05 ). While in control group,the score of adverse reactions was a little higher than before treatment,but the difference was not significant. Conclusion Madopar and pramipexole has better efficacy and high safety in treatment of Parkinson's disease.